Pfizer (NYSE:PFE) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE) in a research note published on Monday, Benzinga reports. The brokerage currently has a $45.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on PFE. Argus lowered shares of Pfizer from a buy rating to a hold rating in a report on Friday, March 22nd. TD Cowen downgraded Pfizer from an outperform rating to a market perform rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Finally, Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a buy rating and a $36.00 price objective for the company. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $36.88.

Pfizer Price Performance

Shares of PFE stock opened at $25.90 on Monday. Pfizer has a twelve month low of $25.61 and a twelve month high of $41.33. The stock has a market capitalization of $146.66 billion, a price-to-earnings ratio of 71.94, a P/E/G ratio of 1.16 and a beta of 0.61. The stock has a fifty day simple moving average of $27.27 and a two-hundred day simple moving average of $28.84. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. On average, analysts predict that Pfizer will post 2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently added to or reduced their stakes in the stock. RB Capital Management LLC increased its holdings in shares of Pfizer by 6.7% during the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its stake in Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the last quarter. United Bank raised its position in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC lifted its stake in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.